Back to all announcements

DJ AfriAg Global Plc Opening of Global Center for Medical Cannabis Therapy

19 September 2019 
                               AfriAg Global PLC 
                          ('AfriAg' or the 'Company') 
 Grand Opening of Doc's Place International, Inc. ('Doc's Place') and Apollon 
                   Formularies Jamaica, Ltd. on 25 October. 
                        Weekend Media Release, Jamaica 
AfriAg Global PLC, a company whose shares are admitted to trading on London's 
NEX Exchange, is pleased to announce that over the past weekend in Jamaica 
Apollon Formularies Jamaica, Ltd.  notified the public that the grand opening 
of the first Global Center for Medical Cannabis Therapy will take place  on 
25th October 2019 in Negril, Jamaica at the facilities of Doc's Place 
International, Inc.  Wired JA Online News released an article on 14 September, 
announcing the opening ( 
in-wired-ja-news-today). The opening ceremony will include a Keynote speech by 
the Jamaican Minister of Commerce, Industry, Agriculture and Fisheries, the 
Hon. Audley Shaw, whose responsibilities include  authority over the Cannabis 
Licensing Authority (CLA) . 
Apollon Formularies Jamaica. Ltd. also issued  a media release in Jamaica over 
the weekend, stating that Jamaican legislation continues to create a solid 
framework within which to operate as it now moves to capitalise on the  revenue 
earning potential and the further advancement of medical knowledge of the 
medicinal cannabis space.  The Company beleives Apollon Formularies Jamaica, 
Ltd. sits at the forefront of scientific endeavour in the medicial cannabis 
space, with the opening of this state of the art, next generation 
master-planned wellness and treatment facility as well as the most modern and 
licenced processing and production facility in Jamaica. 
AfriAg Global's relationship with Apollon Formularies Ltd: 
As previously announced, AfriAg completed an investment in Apollon Formularies 
Ltd ("Apollon UK") of 2.325 per cent of Apollon UK's issued share capital and 
is in negotiations with Apollon UK  and a majority of its shareholders to 
acquire all the issued and outstanding shares owned by shareholders. Further 
investments in, or acquisition of, Apollon UK, are subject to shareholder and 
regulatory approvals.   Apollon UK is an indirect investor in Apollon 
Formularies Jamaica, Ltd. and will have the right to receive 95 percent of the 
net profit of Apollon Formularies Jamaica, Ltd.  Apollon UK also has a right to 
acquire 90 percent of the issued and outstanding stock of Doc's Place 
International, Inc. 
Apollon Formularies Jamaica, Ltd. and Doc's Place have completed a successful 
six-week pilot opening for the treatment of patients which started on Thursday 
1st August 2019, to coincide with Emancipation Day and the start of the 
Jamaican tourist season. 
The Doc's Place facility which will have its official opening on Friday 25th 
October 2019, is a joint venture between Doc's Place International, Inc., a 
health and wellness resort, and Apollon Formularies Jamaica, Ltd. It is located 
at Doc's Place, Hotel and Resort Centre in Negril's West End. 
The goal of the Medical Cannabis Therapy Centre is to provide an environment 
that enhances the quality of life for those being served. It is modelled on 
treatment centres, spas, resorts, and hotels, that provide hospitality-oriented 
services in combination with personal care and well-being services. 
CEO of Doc's Place and a director of Apollon Formularies Jamaica, Ltd., Stephen 
D. Barnhill, MD, said, "This strategic relationship provides patients worldwide 
with the opportunity to receive world-class medical cannabis treatments 
provided by licensed physicians with special expertise in treating with medical 
cannabis-based pharmaceuticals in a safe, professional, medical and legal 
Commenting on the new facility, Medical Director of Doc's Place International, 
Inc. and a U.S. board-certified neurosurgeon, Anthony Hall, MD, said, "We are 
very excited about the opening of the world's first  Global Center of 
Excellence for Medical Cannabis Therapy in Negril, Jamaica, which will provide 
patients with specialized medical care for the myriad of conditions shown to be 
beneficially treated with medical cannabis pharmaceuticals in a Federally legal 
environment." Dr. Hall is supported by a team, which includes Dr. Marjorie 
Vassell and Dr. Alfred Dawes. 
Chief Science Officer of Doc's Place International and former professor and 
director of Clinical Chemistry at MD Anderson Cancer Centre, Herb Fritsche, 
Ph.D., pointed out:  "Having the world's first Global Center of Excellence for 
Medical Cannabis Therapy gives us the opportunity to do state-of-the-art 
research, clinical trials and development based on patient outcomes data, 
create and adapt pharmaceutical formulations, establish accurate therapeutic 
doses and develop genomic markers to better determine the proper course of 
treatment for patients being treated by our excellent medical team using 
Apollon Formularies Jamaica, Ltd.'s award-winning medical cannabis strains and 
cannabis-based pharmaceutical formulary." 
Paul Burke, CEO of Apollon Formularies Jamaica, Ltd.,  said, "We are pleased 
that we have a strategic relationship with Doc's Place International to open 
the world's first Global Center of Excellence for Medical Cannabis Therapy in 
Negril, Jamaica, and to provide legal, state-of-the-art, quality-controlled 
medical cannabis-based pharmaceuticals to the excellent medical team treating 
these patients." 
Jamaica's Ministry of Tourism has the development of health and wellness 
tourism as one of its pillars for growing the tourism industry, and the 
Ministry of Health and Wellness recently said they hope to attract over 100,000 
medical tourists to the island within the next 10 years. Doc's Place 
International's Global Center for Medical Cannabis Therapy aims to be a major 
contributor to this increase in medical tourists to the island. 
In their media publication over the weekend, Apollon Formularies Jamaica, Ltd. 
stated that Medical Cannabis has been shown to be beneficial in a myriad of 
conditions, including prostate cancer, breast cancer, brain cancer, nausea/ 
vomiting (chemotherapy), nausea/vomiting (sea sickness), post traumatic stress 
disorder (PTSD), chronic pain, arthritis, crohn's disease/ulcerative colitis, 
epilepsy, glaucoma, HIV, Alzheimer's Disease, Lupus (SLE), opioid/narcotic 
rehabilitation, Parkinson's Disease, anxiety disorders and sleep disorders. 
Notice Regarding Forward-Looking Statements 
This announcement includes "forward-looking statements" involving the Company, 
the other entities referenced in this announcement, and the respective 
subsidiaries, affiliates and associates of the Company and such other entities 
(collective, the "Involved Entities"), which include all statements other than 
statements of historical facts, including, without limitation, those regarding 
the financial position, business strategy, plans and objectives of management 
for future operations, and any statements preceded by, followed by or that 
include forward-looking terminology such as the words "targets", "believes", 
"estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", 
"would", "should", "could" or similar expressions or the negative thereof. Such 
forward-looking statements involve known and unknown risks, uncertainties and 
other important factors beyond the control of the Involved Entities that could 
cause the actual results, performance or achievements of the Involved Entities 
to be materially different from future results, performance or achievements 
expressed or implied by such forward-looking statements. Such forward-looking 
statements are based on numerous assumptions regarding the present and future 
business strategies of the Involved Entities and the environment in which the 
Involved Entities will operate in the future. These forward-looking statements 
speak only as of the date of this announcement. The Company, on behalf of 
itself and each of the Involved Entities, expressly disclaims any obligation or 
undertaking to disseminate any updates or revisions to any forward-looking 
statements contained in this announcement to reflect any change in expectations 
of any Involved Entities with regard thereto or any change in events, 
conditions or circumstances on which any such statements are based. As a result 
of these factors, readers are cautioned not to rely on any forward-looking 
The directors of the Company accept responsibility for the contents of this 
For further information on AfriAg Global please visit the 
or please contact; 
AfriAg Global Plc: 
David Lenigas (Executive Chairman) 
                                                    +44 (0)20 7440 0640 
Peterhouse Capital Limited 
                         +44 (0)20 7469 0930 
Guy Miller/Allie Feuerlein 

(END) Dow Jones Newswires

September 19, 2019 03:44 ET (07:44 GMT)